Janssen’s Stelara overtakes Takeda’s Entyvio as the leading alternative MOA in Crohn’s Disease, but pressure is on to maximize IBD value in advance of pipeline drugs from Celgene (mongersen, ozanimod), Roche/Genentech (etrolizumab) and Pfizer (Xeljanz)
According to RealWorld Dynamix: Biologic Switching in IBD, an annual patient chart analysis conducted by Spherix Global Insights, biologic use in IBD is becoming increasingly dynamic, with switching rates up significantly in both Ulcerative Colitis (UC) and Crohn’s Disease (CD) compared to 2016. Furthermore, switching patterns have changed dramatically with the recent introduction of Stelara.
EXTON, Pa., June 13, 2017 /PRNewswire/ — Spherix Global Insights announces the release of RealWorld Dynamix: Biologic Switching in IBD, which engaged 187 gastroenterologists to conduct an in-depth review of over 1,000 IBD patients that recently switched between biologic brands. Report analysis reveals that Janssen has offset Stelara losses in psoriatic arthritis with its new indication in Crohn’s Disease, where the IL-12/23 inhibitor has leapfrogged Entyvio as the preferred non-TNF, second-line agent.
Although the pattern of sequencing two anti-TNF inhibitors remains dominant, use of alternative MOAs in the second-line biologic setting has increased significantly since 2016. Gastroenterologist’s intentions around subsequent switching indicate that they will not waste time assessing patient response. If the treatment goals for the patient are not met, 70% of patients will be switched again within six months.
In UC, Entyvio maintains the position of preferred non-TNF agent, but the lack of an indication does not seem to be stopping gastroenterologists from using Stelara in these patients. Indeed, off-label use of Stelara is projected to pick up nearly one-third of the UC patients as they move from their second to third-line biologic.
Although the participating gastroenterologists point to clinical and endoscopic remission as the leading triggers for a biologic switch, they also note that patients have significant input into the decision, in some cases being the primary driver.
In common with other autoimmune conditions where biologics are prevalent, the physicians in the IBD market are increasing their use of biologics, using them earlier, switching faster, and embracing agents with novel MOAs. With this market acceleration and hunger for new assets, drugs such as Entyvio and Stelara need to focus on growth, but also on solidifying their gains against potential newcomers such as Pfizer’s Xeljanz, Celgene’s mongersen and ozanimod and Roche/Genentech’s etrolizumab.
Gastroenterologists report that close to half of their IBD patients are not optimally managed on their current agent, creating a ripe environment for new entrants in the future switching market.
To view media coverage of this release, click here.
About RealWorld Dynamix
RealWorld Dynamix™ is a research report derived from a robust patient audit focused on over 1,000 IBD patients recently switched from one biologic brand to another. Unlike claims data, the analysis includes physician assessment, rationale for treatment decisions and future intent related to biologic selection. In addition, key variables such as patient engagement level, the influence of the payer, socioeconomic metrics, QOL metrics, co-morbidities, concomitant medications, and lab test results are also included to provide a comprehensive analysis of the patient journey.
About Spherix Global Insights
Spherix Global Insights is an independent business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
All company, brand or product names in this document are trademarks of their respective holders.
For more information contact:
Lynn Price, Immunology Franchise Head